Axogen, Inc. AXGN 深 沪
已收盘 02-06 16:00:00 美东时间
34.93
+1.030
+3.04%
华盛通- 最 高35.645
- 今 开34.26
- 成交量 82.22万股
- 最 低 34.26
- 昨 收 33.90
- 总市值 17.52亿
- 52周最高 35.9999
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 9.215
- 委 比 46.22%
- 总股本 5016.92万
- 历史最高 56.85
- 量 比 0.73
- 振 幅 4.09%
- 历史最低 1.10
- 每 手 1
- 风险率 7.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Axogen Prices Upsized $124 Million Stock Offering
Axogen stock fell Thursday with a session volume of 1.92 million, priced its upsized underwritten public offering at $31.00 per share.
01-23 01:42
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) shares rose 48.6% to $33.13 durin...
01-22 20:05
Axogen shares are trading lower after the company announced an $85 million proposed public offering.
Axogen shares are trading lower after the company announced an $85 million prop...
01-22 05:18
Axogen Raises FY2025 Sales Guidance from $222.800M to $225.200M vs $223.339M Est
Axogen (NASDAQ:AXGN) raises FY2025 sales outlook from $222.800 million to $225.200 million vs $223.339 million estimate.
01-12 20:15
Axogen Sees Q4 Sales $59.900M vs $58.000M Est
Axogen (NASDAQ:AXGN) sees Q4 sales of $59.900 million vs $58.000 million analyst estimate.
01-12 20:15
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
AxoGen Approves New CFO Compensation and Agreement
AxoGen ( ($AXGN) ) has provided an update. On December 3, 2025, AxoGen, Inc.’s ...
2025-12-06 05:29
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of UiPath Inc. (NYSE:PATH) rose sharply in pre-market trading after the ...
2025-12-04 17:48
Axogen gets FDA OK for Avance’s biologics license application
Axogen (AXGN) on Wednesday said that the U.S. Food and Drug Administration has approved the biologics license application for AVANCE (acellular nerve allograft-arwx). Avance is an acellular nerve scaf...
2025-12-04 13:13
